Q-omics provides the consensus-scored GNAS profile across patient tissues and cancer cell-line models. GNAS expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GNAS is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, GNAS protein abundance shows 19,538 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UVM, LIHC, and PDAC as cancer lineages where GNAS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GNAS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GNAS survival associations across molecular data types. GNAS RNA expression shows survival associations in the most cancer types (26), followed by mutation status (9) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GNAS RNA expression–survival associations across cancer types. High GNAS expression shows unfavorable associations in UVM, KIRC, MESO, KIRP, LIHC and STAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for GNAS RNA expression.
This table summarizes GNAS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 9. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GNAS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GNAS shows higher tumor expression in LIHC, KIRP, UCEC, COAD, LUSC and BRCA. The LIHC box plot shows higher GNAS RNA expression in tumor versus normal tissue (log2 FC = +0.719, t-test p < 0.001).
This table shows molecular features associated with GNAS in patient tissues and cancer cell lines. In patient samples, GNAS shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, GNAS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
